Lipid mediators and allergic diseases

Fanning, Laura B.; Boyce, Joshua A.

doi:10.1016/j.anai.2013.06.031

Cited by 64 publications

(54 citation statements)

References 103 publications

(117 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unsaturated fatty acids mainly bound to the sn-2 position of glycerolipids can be easily deacylated by phospholipase A 2 [43]. Higher unsaturated fatty acids, for instance arachidonic acid, can be hydrolyzed in this way followed by metabolization in two directions producing prostanoids and eicosanoids [44]. Membranes adjust their composition according to the environmental conditions.…”

Section: Influence Of Fatty Chain Modificationsmentioning

confidence: 99%

Phase behavior of selected artificial lipids

Dobner

Brezesinski

2014

Current Opinion in Colloid & Interface Science

View full text Add to dashboard Cite

Section: Influence Of Fatty Chain Modificationsmentioning

confidence: 99%

Phase behavior of selected artificial lipids

Dobner

Brezesinski

2014

Current Opinion in Colloid & Interface Science

View full text Add to dashboard Cite

“…Prostaglandins and leukotrienes, collectively known as eicosanoids, play an important role in the pathogenesis of a number of obstructive lung diseases [171]. Expression of cyclooxygenase-2 (COX-2) is reduced in fibroblasts isolated from animals in models of asthma or pulmonary fibrosis, whereas COX-2 expression has been shown to be increased in lung sections of COPD patients [172,173].…”

Section: Eicosanoidsmentioning

confidence: 99%

Beyond TGFβ – Novel ways to target airway and parenchymal fibrosis

Boorsma¹,

Dekkers²,

Dijk³

et al. 2014

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

“…Like COX inhibitors, CYP and LO inhibitors have significant therapeutic potential. The 5-LO inhibitor, zileuton, is currently being used to treat asthma and sEH inhibitors are being evaluated for the treatment of hypertension, diabetes, and chronic obstructive pulmonary disease (34, 56). …”

Section: Pharmacological and Genetic Manipulation Of Pathwaysmentioning

confidence: 99%

Cytochrome P450 and Lipoxygenase Metabolites on Renal Function

Imig

Khan

2015

Comprehensive Physiology

View full text Add to dashboard Cite

Arachidonic acid metabolites have a myriad of biological actions including effects on the kidney to alter renal hemodynamics and tubular transport processes. Cyclooxygenase metabolites are products of an arachidonic acid enzymatic pathway that has been extensively studied in regards to renal function. Two lesser-known enzymatic pathways of arachidonic acid metabolism are the lipoxygenase (LO) and cytochrome P450 (CYP) pathways. The importance of LO and CYP metabolites to renal hemodynamics and tubular transport processes is now being recognized. LO and CYP metabolites have actions to alter renal blood flow and glomerular filtration rate. Proximal and distal tubular sodium transport and fluid and electrolyte homeostasis are also significantly influenced by renal CYP and LO levels. Metabolites of the LO and CYP pathways also have renal actions that influence renal inflammation, proliferation, and apoptotic processes at vascular and epithelial cells. These renal LO and CYP pathway actions occur through generation of specific metabolites and cell-signaling mechanisms. Even though the renal physiological importance and actions for LO and CYP metabolites are readily apparent, major gaps remain in our understanding of these lipid mediators to renal function. Future studies will be needed to fill these major gaps regarding LO and CYP metabolites on renal function.

show abstract

Lipid mediators and allergic diseases

Cited by 64 publications

References 103 publications

Phase behavior of selected artificial lipids

Phase behavior of selected artificial lipids

Beyond TGFβ – Novel ways to target airway and parenchymal fibrosis

Cytochrome P450 and Lipoxygenase Metabolites on Renal Function

Contact Info

Product

Resources

About